CDK4 and breast carcinoma: However, their use is associated with a range of side effects, most notably neutropenia.[7, 12, 13] Hematopoietic stem cells (HSCs) rely on CDK6 to drive G1 progression, whereas most cell types, including breast cancer cells, utilize CDK4.